3,091 Shares in Kenvue Inc. (NYSE:KVUE) Bought by Brooklyn Investment Group

Brooklyn Investment Group bought a new position in shares of Kenvue Inc. (NYSE:KVUE) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 3,091 shares of the company’s stock, valued at approximately $71,000.

Other large investors have also bought and sold shares of the company. Riverview Trust Co bought a new position in Kenvue during the 3rd quarter worth $30,000. Ashton Thomas Securities LLC acquired a new stake in Kenvue during the 3rd quarter worth about $35,000. Studio Investment Management LLC grew its holdings in Kenvue by 52.1% during the 2nd quarter. Studio Investment Management LLC now owns 2,468 shares of the company’s stock worth $45,000 after acquiring an additional 845 shares during the period. Deseret Mutual Benefit Administrators grew its holdings in Kenvue by 49.7% during the 3rd quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company’s stock worth $45,000 after acquiring an additional 651 shares during the period. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new stake in Kenvue during the 2nd quarter worth about $61,000. 97.64% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts have weighed in on KVUE shares. JPMorgan Chase & Co. increased their price target on Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Jefferies Financial Group started coverage on Kenvue in a research note on Tuesday, September 24th. They issued a “buy” rating and a $27.00 target price for the company. Royal Bank of Canada downgraded Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 target price for the company. in a research note on Tuesday, September 24th. UBS Group lifted their price target on Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a research note on Wednesday, August 7th. Finally, Deutsche Bank Aktiengesellschaft lifted their target price on shares of Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $22.64.

Kenvue Stock Up 0.0 %

Shares of NYSE:KVUE opened at $24.13 on Friday. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $24.46. The firm has a fifty day moving average of $22.92 and a 200 day moving average of $20.96. The firm has a market capitalization of $46.26 billion, a PE ratio of 43.87, a price-to-earnings-growth ratio of 2.20 and a beta of 1.36. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, November 7th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.27 by $0.01. The firm had revenue of $3.90 billion during the quarter, compared to the consensus estimate of $3.92 billion. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The company’s quarterly revenue was down .4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.31 earnings per share. As a group, research analysts anticipate that Kenvue Inc. will post 1.07 EPS for the current fiscal year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, November 27th. Stockholders of record on Wednesday, November 13th were paid a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a dividend yield of 3.40%. The ex-dividend date of this dividend was Wednesday, November 13th. Kenvue’s dividend payout ratio (DPR) is 149.09%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.